Wilson Sonsini - ECVC

Life Sciences

Our Industry Coverage

With one of the largest life sciences practices in the U.S., Wilson Sonsini’s industry legacy dates to the formative years of biotech and medical device. Working closely with scientists and entrepreneurs who grew their companies into thriving businesses, we have worked alongside to support their endeavors from whiteboard to clinical trial and beyond.

Industry Highlights

Celebrating our founders’ successes

2024

USANA Health Sciences on Acquisition of Hiya Health

Nutritional Supplements, Functional Foods and Personal Care Products

2024

LaNova Medicines on Exclusive Global License with Merck

Biotechnology

2024

Borealis Biosciences Announces $150 Million Series A and Strategic Collaboration Funding

RNA Medicines

2023

DTx Pharma Announces Acquisition by Novartis

Biotechnology

2023

Aspect Biosystems Announces $2.7 Billion Collaboration with Novo Nordisk

Biotechnology

2023

Chroma Medicine Lands $135 Million Series B Financing

Genomics

2022

Arcellx, Inc. Raises $124 Million IPO

Biotechnology

2021

Ventyx Biosciences Closes IPO at $175 Million

Biotechnology, Pharmaceuticals

2021

Tenaya Therapeutics Completes IPO Worth $207 Million

Biotechnology

2021

Kinnate Biopharma Raises $276 Million IPO

Drug Discovery, Pharmaceuticals

2020

Seer IPO Raises $175 Million in Nasdaq Debut

Decision / Risk Analysis

2020

PMV Pharmaceuticals Joins Nasdaq with $211 Million IPO

Drug Discovery

2020

Athira Pharma Closes $204 Million IPO

Drug Discovery

2020

ALX Oncology Prices IPO at $161 Million

Immuno-Oncology

2020

Applied Molecular Transport Closes IPO at $154 Million

Pharmaceuticals

2020

Oric Pharmaceuticals IPO Raises $120 Million

Drug Discovery

2019

Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

Generics and Specialty Pharmaceuticals

Attorneys

focused
on this
industry

See all ECVC attorneys

Mark
Holloway

See all ECVC attorneys

recent news

we want to share
with you

Wilson Sonsini Advises Investors on Callio Therapeutics' $187 Million Series A

Wilson Sonsini Advises Investors on Callio Therapeutics' $187 Million Series A

Client Highlights03/04/25
Wilson Sonsini Advises Junevity on $10 Million Seed Funding
See all news
See all news

other industries

we have covered